Literature DB >> 29853257

Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes.

José Luis Izquierdo1, Marc Miravitlles2, Cristina Esquinas3, Maite Pérez4, Myriam Calle5, José Luis López Campos6, José Miguel Rodríguez González-Moro7, Ciro Casanova8, Cristóbal Esteban9, Pilar de Lucas10.   

Abstract

INTRODUCTION: The objective of this study was to analyze the clinical characteristics of COPD patients attending general respiratory clinics, adherence to clinical guidelines, classification accuracy, and therapeutic management.
METHOD: Multicenter, cross-sectional study, with the primary objective of describing the number, intensity, and variability of symptoms in COPD patients. Data were collected in 2015 by 300 pulmonologists who evaluated a total of 3,010 patients, of which 2,669 (88.6%) were eligible for analysis.
RESULTS: A total of 22% were active smokers, notably 21% and 17% of GOLD groups C and D, and 17% and 19% of exacerbators in the GesEPOC classification; 62.3% had associated comorbidities. The diagnostic process was characterized by limited use of tests such as diffusion capacity or lung volumes, even in the more severe GOLD groups or the GesEPOC exacerbator phenotypes. The use of multidimensional scales, such as BODE (12%), and specific rehabilitation protocols was also rare. Treatment was based on different combinations of bronchodilators and inhaled corticosteroids. Methylxanthines were used in very few patients (7%).
CONCLUSIONS: A large proportion of COPD patients seen in respiratory clinics have non-complex disease and pulmonology tests are rarely performed. Our study confirms a slight change in treatments and the frequent association with comorbidities that can modify the clinical presentation of the patient.
Copyright © 2018 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  COPD; Consultas de neumología; EPOC; GOLD; GesEPOC; Respiratory clinics

Mesh:

Year:  2018        PMID: 29853257     DOI: 10.1016/j.arbres.2018.03.021

Source DB:  PubMed          Journal:  Arch Bronconeumol (Engl Ed)        ISSN: 0300-2896            Impact factor:   4.872


  7 in total

1.  Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective.

Authors:  Melanie Schroeder; Nicole Benjamin; Laura Atienza; Chandroday Biswas; Alan Martin; John D Whalen; José Luis Izquierdo Alonso; Juan Antonio Riesco Miranda; Juan José Soler-Cataluña; Alicia Huerta; Afisi S Ismaila
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-07-10

2.  Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database.

Authors:  Jennifer K Quint; Jukka Montonen; Daina B Esposito; Xintong He; Leslie Koerner; Laura Wallace; Alberto de la Hoz; Marc Miravitlles
Journal:  Adv Ther       Date:  2021-03-15       Impact factor: 3.845

3.  Quantification of inaccurate diagnosis of COPD in primary care medicine: an analysis of the COACH clinical audit.

Authors:  María Abad-Arranz; Ana Moran-Rodríguez; Enrique Mascarós Balaguer; Carmen Quintana Velasco; Laura Abad Polo; Sara Núñez Palomo; Jaime Gonzálvez Rey; Ana María Fernández Vargas; Antonio Hidalgo Requena; Jose Manuel Helguera Quevedo; Marina García Pardo; Jose Luis Lopez-Campos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-06-06

4.  Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data.

Authors:  Elena García Castillo; Tamara Alonso Pérez; Julio Ancochea; Maria Teresa Pastor Sanz; Pere Almagro; Pablo Martínez-Camblor; Marc Miravitlles; Mónica Rodríguez-Carballeira; Annie Navarro; Bernd Lamprecht; Ana S Ramírez-García Luna; Bernhard Kaiser; Inmaculada Alfageme; Ciro Casanova; Cristóbal Esteban; Juan J Soler-Cataluña; Juan P de-Torres; Bartolomé R Celli; Jose M Marín; Gerben Ter Riet; Patricia Sobradillo; Peter Lange; Judith Garcia-Aymerich; Josep M Anto; Alice M Turner; MeiLan K Han; Arnulf Langhammer; Sigrid Anna Aalberg Vikjord; Alice Sternberg; Linda Leivseth; Per Bakke; Ane Johannessen; Toru Oga; Borja G Cosío; Andrés Echazarreta; Nicolás Roche; Pierre-Régis Burgel; Don D Sin; Milo A Puhan; Jose Luis López-Campos; Laura Carrasco; Joan B Soriano
Journal:  ERJ Open Res       Date:  2020-11-02

5.  Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD.

Authors:  Mònica Monteagudo; Miriam Barrecheguren; Iryna Solntseva; Nafeesa Dhalwani; Alison Booth; Alexa Nuñez; Dimitra Lambrelli; Marc Miravitlles
Journal:  NPJ Prim Care Respir Med       Date:  2021-03-22       Impact factor: 2.871

6.  Economic Impact of Low Adherence to COPD Management Guidelines in Spain.

Authors:  Marc Miravitlles; Alexandra Solé; Helena Aguilar; Ana Ampudia; Jaume Costa-Samarra; Maria Mallén-Alberdi; Diana Nieves
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-11-16

7.  Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD.

Authors:  Marc Miravitlles; Alicia Marín; Alicia Huerta; David Carcedo; Alba Villacampa; Jaume Puig-Junoy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-07-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.